Have a feature idea you'd love to see implemented?
Let us know!
NMRA Neumora Therapeutics Inc.
Price (delayed)
$9.69
Market cap
$1.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.2
Enterprise value
$1.29B
Highlights
The company's EPS has surged by 74% YoY and by 37% QoQ
The debt has plunged by 55% YoY and by 24% from the previous quarter
The net income has dropped by 89% year-on-year and by 7% since the previous quarter
Neumora Therapeutics's quick ratio has decreased by 38% YoY and by 33% QoQ
Key stats
What are the main financial stats of NMRA
Market
Valuations
Earnings
Shares outstanding
161.56M
Market cap
$1.57B
Enterprise value
$1.29B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$293.25M
EBITDA
-$289.29M
Free cash flow
-$184.08M
Per share
Balance sheet
Liquidity
EPS
-$1.2
Free cash flow per share
-$1.15
Book value per share
$2
Revenue per share
$0
TBVPS
$2.21
Total assets
$352.54M
Total liabilities
$31.8M
Debt
$2.75M
Equity
$320.74M
Working capital
$316.87M
Debt to equity
0.01
Current ratio
10.98
Quick ratio
10.79
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69%
Return on equity
-73.6%
Return on invested capital
-187.2%
Return on capital employed
-91.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NMRA stock price
How has the Neumora Therapeutics stock price performed over time
Intraday
-1.02%
1 week
-17.11%
1 month
-31.03%
1 year
-17.11%
YTD
-43.17%
QTD
-26.65%
Financial performance
How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$314.55M
Net income
-$293.7M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 89% year-on-year and by 7% since the previous quarter
Neumora Therapeutics's operating income has shrunk by 86% YoY and by 7% QoQ
Growth
What is Neumora Therapeutics's growth rate over time
Valuation
What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
4.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 74% YoY and by 37% QoQ
Neumora Therapeutics's equity has decreased by 37% YoY and by 16% QoQ
The stock's P/B is 11% below its last 4 quarters average of 5.4
Efficiency
How efficient is Neumora Therapeutics business performance
The ROE has plunged by 143% YoY and by 20% from the previous quarter
The ROA has plunged by 142% YoY and by 19% from the previous quarter
NMRA's return on invested capital is down by 30% year-on-year and by 18% since the previous quarter
Dividends
What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NMRA.
Financial health
How did Neumora Therapeutics financials performed over time
NMRA's current ratio is down by 39% year-on-year and by 36% since the previous quarter
Neumora Therapeutics's quick ratio has decreased by 38% YoY and by 33% QoQ
The debt is 99% less than the equity
The debt has plunged by 55% YoY and by 24% from the previous quarter
Neumora Therapeutics's equity has decreased by 37% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.